Connect your AI

Bio-Techne TECH Purchases of equity securities

Purchases of equity securities at other companies

Lantheus HoldingsLNTH

——

Other financials

Income statement

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation

Market cap$9.07B-11.8%

Enterprise value$9.15B-13.6%

P/E60.6×+13.6×

P/S7.5×-1.0×

Profitability

Gross margin65%-0.8pp

Operating margin14.2%-7.9pp

Net margin10.9%-6.7pp

FCF margin22.3%+4.0pp

Returns & leverage

Return on equity6.5%-3.9pp

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireEquitySecuritiesFvNi.

The official record: Bio-Techne’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's purchases of equity securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bio-Techne's purchases of equity securities?: Bio-Techne (TECH) reported purchases of equity securities of $15M in Q3 2024.
What does purchases of equity securities mean?: Cash spent purchasing equity securities for the investment portfolio.